Rubella virus envelope glycoproteins E1 and E2 (RuV E1/E2)

Rubella virus envelope glycoproteins E1 and E2 are the primary surface proteins of the Rubella virus (RuV), responsible for mediating viral entry into host cells (Nature, 2013; MicrobeNotes, 2024). E1 is a class II fusion protein that facilitates the fusion of the viral envelope with the host endosomal membrane, while E2 acts as a chaperone for E1 folding and transport (J Cell Biol, 1993; Nature, 2013). These glycoproteins are the principal targets of the host immune response, particularly for neutralizing antibodies that prevent infection (NIH, 2024; Nature, 2013). In clinical practice, they are the primary antigens used in live-attenuated vaccines, such as the MMR vaccine, to induce long-term immunity (CDC, 2024; TechNet-21, 2015). Understanding their structure and function is critical for diagnosing rubella and preventing congenital rubella syndrome, a severe condition resulting from maternal infection during pregnancy (Wikipedia, 2024; Creative Diagnostics, 2024). Additionally, research into these proteins has identified them as potential targets for antiviral therapies, such as nitazoxanide, which may interfere with their trafficking and assembly (J Infect Dis, 2017).

Other names

E1 glycoproteinE2 glycoproteinRubella virus spike proteinsRuV E1RuV E2Envelope glycoprotein E1Envelope glycoprotein E2Rubella virus E1/E2 heterodimer

Neutralization of viral entry by blocking attachment or membrane fusion through antibody binding to E1 and E2 epitopes (Vaccines/Immunoglobulins); Inhibition of E1-E2 intracellular trafficking and complex formation (Nitazoxanide).